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CHAPTER I
INTRODUCTION

Alcohol (ethyl alcohol, or EtOH) is the most important drug of dependence in
all industrialized countries. The social and clinical problems that arise from alcohol's
widespread abuse are now well documented. In the U.S. alone, approximately 18
million adults exhibit some form of alcoholism, alcohol dependence, or alcohol abuse
(Van Natta, et al 1984). Recent studies of current trends in alcohol drinking behavior
indicate that bouts of high level alcohol consumption over short periods of time, termed
"binge-drinking" episodes, are becoming more common, especially amongst young
adults in the U.S. (Meilman et al 1990). Binge drinking is believed to be one of
several behavioral characteristics involved in the development of chronic alcoholism
(Richards, et al 1990). While many studies have been undertaken to determine the
effects of chronic alcohol consumption on health in alcoholic subjects and in animal
models of alcoholism, less is known about the deleterious effects of short-term, binge
alcohol consumption.
Several elements of the endocrine system are known to be adversely affected by
alcohol, including the hypothalamic-pituitary-growth hormone (GH) axis, and the
hypothalamic-pituitary-prolactin (PRL) axis (Zakhari, 1992). GH and PRL are closely

1

2

related pituitary hormones which subserve a wide variety of essential functions in
mammals, such as regulation of growth, reproduction, maintenance of lactation,
intermediary metabolism and immune responsiveness (Hadley, 1988). The suppressive
effect of EtOH on GH secretion and its stimulating effect on PRL release have been
previously investigated, and both a pituitary (Redmond, 1980; Dees, et al 1988;
Emanuele, et al 1989; Sontag and Boyd 1989) and a hypothalamic/central nervous
system locus of EtOH action have been postulated (Conway and Maureci, 1991).
Despite this research, there is at present no consensus on EtOH's precise site of action,
nor is there a complete mechanistic explanation for the differential effects of EtOH on
these two hormones.

The hypothesis to be tested is that, similar to effects on other

pituitary hormone systems, EtOH acts at numerous levels within the GH and PRL axes
and exerts its deleterious effects through numerous mechanisms.
Therefore, the specific aims of this dissertation research are: 1) to investigate
the potential site(s) of action of acute EtOH within the GH and PRL axes, and 2) to
further elucidate the biochemical and molecular mechanisms responsible for the EtOHinduced fall in serum GH and the concomitant rise in serum PRL levels. To address
the aims of this research, an in vivo rat model approximating binge alcohol
consumption was created. Adult male Sprague-Dawley rats, aged 60-90 days, were
given acute, high level alcohol doses (3 g/kg) via an intraperitoneal (i.p.) injection,
sacrificed at various time points after injection, and assessed for various endocrine
parameters, compared to saline-injected controls. These "single binge" experiments
were followed up with "double binge" studies to determine if the system reacts in a

3

similar fashion after repeated EtOH exposure.
This dissertation describes the effects of EtOH at the pituitary level, on both GH
andPRL synthesis and secretion, and at the hypothalamic level on GHRH and SRIF
synthesis and secretion. At the molecular level, steady-state messenger RNA
(mRNA) levels for these hormones were measured, as well as the transcription rates for
the piuitary genes.

Additional mechanisms were investigated, including EtOH's

effects on second messenger systems involved in GH and PRL gene expression.

CHAPTER II
REVIEW OF RELATED LITERATURE

A. The Growth Hormone (GH) Axis
Growth hormone, (GH) is an important anterior pituitary hormone required for
normal postnatal growth, particularly long-bone growth, and is also involved in a
variety of other physiological functions such as maintenance of nitrogen, mineral, lipid,
and carbohydrate metabolism (Hadley, 1988). While GH has long been recognized as
a regulator of body growth, it is produced even in adult non-growing animals and
humans, and evidence is increasing that this hormone is needed throughout life for the
normal function of tissues and organs (Thorner and Vance, 1988). Two of the more
recent and intriguing additions to the growing list of GH functions which are carried
out into adulthood are modulation of the immune system (Berczi, et al 1991), and
reversal of some of the physical aspects of aging, such as improved muscle tone and
increase in lean body mass, and reversal of the age-related decrease in bone density in
elderly patients (Rudman, et al 1990).
In mammals, GH is synthesized and secreted from a subpopulation of anterior
pituitary cells known as the somatotropes, the most abundant cell type in the gland
(Martin, 1985). Somatotropes can store a significant amount of GH in cytoplasmic
4
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secretory vesicles. The adult human gland contains 5 to 10 mg of the GH protein
(Murray, et al 1990). Upon stimulation from the hypothalamus and higher brain
centers, GH is released into the general circulation where it binds to specific GH
receptors, located predominantly on liver cells, and also to a lesser degree on bone,
cartilage, kidney, pancreas, testes and hypothalamic cells (Hadley, 1988). Upon
binding to liver cell receptors, GH stimulates the release of liver-derived growth
factors, collectively known as the somatomedins. The primary somatomedin released
in response to GH is somatomedin C, or insulin-like growth factor-1 (IGF-1) (Martin,
1985). Like many endocrine systems, the GH axis is under highly complex regulation
by short and long feedback loops. These feedback loops ensure that hormone levels
remain within certain homeostatic boundaries, which are determined by the
biochemical and physiologic needs of the organism.
It is believed that the majority of GH's growth-promoting effects are mediated

through IGF-1, while the effects on carbohydrate, lipid and protein metabolism and the
proliferative effect on lymphocytes are due to the direct action of GH itself (Martin,
1985; Berczi, et al 1991). The GH protein exists as a 191-amino acid monomer with a
molecular weight of 22 kDa, although 20 kDa and 36 kDa variants have been reported
(Sinha, et al 1987; Bollengier, et al 1988). In the circulation GH has a half-life of
about 20 minutes (Taylor, et al 1969). While in the circulation, it is attached to a
specific GH-binding protein (GHBP) (Martin 1985). Plasma IGF-1 is also bound to
carrier proteins. In contrast to GH, the half-life of IGF-1 in the circulation is about 24
hours. There is little little diurnal variation in the plasma levels of IGF-1 (Martin,
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1985).
GH release is episodic and pulsatile in all species in which it has been
examined. Serum GH may change as much as 10-fold within a few minutes (Murray,
et al 1990). One of the largest increases occurs shortly after the onset of sleep. Other
factors which can stimulate GH release include stress, exercise, hypoglycemia or
fasting, a protein meal, and the amino acid arginine (Murray, et al 1990). The pattern
of GH secretion in rats is sexually dimorphic and greatly influenced by androgens both
during the neonatal and adult periods (Jansson, et al 1985). In male rats, secretory
bursts of GH occur at 3.3 hour intervals interspersed by trough periods during which
GH levels are virtually undetectable (Tannenbaum, et al 1993). In contrast, female rats
exhibit GH pulses that are irregular in timing, more frequent, and of lesser magnitude
than in males. It has been speculated that such differences in pulse amplitude may
account for the larger size of adult male rats versus adult female rats (Bercu, et al
1991). The pulsatile nature of GH release is essential to its effectiveness. A study
utilizing young hypophysectomized (surgical removal of the pituitary) rats fitted with
chronic venous cannulae showed that pulsatile infusions of GH produced a sustained
growth response, whereas continuous infusion of GH led to growth retardation
(Robinson and Clark, 1987). Thus, a plasma GH profile which resembles the
physiological 3-hour episodic secretory pattern in male rats is most effective in
promoting growth.

7

B. Regulation of GH Synthesis and Secretion
GH secretion is regulated by a complex neuroendocrine control system that
includes both neurotransmitters and feedback by hormonal and metabolic substrates.
The final common pathway for the integration of these signals involves two
hypothalamic neuropeptides, which are hypophysiotropic hormones. OH-releasing
hormone (GHRH), a 40-44 residue peptide, exerts stimulatory effects on GH secretion
while somatostatin (SRIF), a tetradecapeptide, exhibits an inhibitory influence
(Hadley, 1988). There are several negative feedback actions in the operation of the
GH axis (Abe, et al 1983). GHRH inhibits its own secretion by hypothalamic neurons
("ultra short-loop" feedback), and simultaneously may augment the release of
somatostatin. GH stimulates the production of somatostatin by the hypothalamus
("short-loop" feedback). IGF-1 tends to inhibit the release of GH by actions both on
the hypothalamus (increased SRIF production) and on the pituitary somatotropes
through diminished responsiveness to GHRH ("long-loop" feedback). A diagrammatic
representation of the mammalian GH axis and its feedback loops is depicted in figure 1.

C. Growth Hormone Releasing- Hormone (GHRH)
In humans and rats, the majority of GHRH cell bodies are located in the medial
basal hypothalamus (MBH), specifically in the lateral zone of the arcuate nucleus
(Martin, 1985). These neurons project to nerve endings in the median eminence which
abut next to capillaries of the pituitary portal vessel circulation, the vascular link
between the hypothalamus and the pituitary (Maclean and Jackson, 1988) . . The entire
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Figure 1. Diagrammatic representation of the hypothalmic-pituitary-growth hormone
axis, showing positive and negative feedback loops.
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GHRH gene has been isolated and sequenced from genomic libraries. The gene spans
10 kb, including 5 exons and 4 introns. Exons 1 and 2 encode the 5' untranslated
regions, exons 2-4 encode most of the 108 amino acid prepro-hormone and exon 3
encodes almost all of the bioactive portion of mature GHRH (Mayo, et al 1985).
GHRH expression is believed to be regulated by a number of factors, including a
short-loop negative feedback of GH on the hypothalamus and a long-loop negative
feedback of IGF-1. There is also evidence for paracrine regulation within the
hypothalamus by SRIF (Frohman, et al 1990). The regulatory sequences in the 5'
untranscribed regions of the GHRH gene are still being determined, however there are
reports describing regions with partial homology to cAMP response elements (Frohman
and Jansson, 1986). The GHRH gene is expressed primarily in the hypothalmus, but
mRNA and protein secretion have also been reported in the placenta (Baird, et al 1985)
and testis (Berry and Pescovitz, 1988).

The exact function of this "ectopic" expression

of GHRH is at this point unclear.
GHRH released from the hypothalamus travels via the pituitary portal vessels,
and binds to specific receptors on the pituitary somatotroph. Most evidence suggests
that these receptors are coupled directly to the stimulatory GTP (guanine nucleotide)
binding protein, Gs, which in turn activates the the catalytic subunit of adenylate
cyclase (AC) to form cAMP (Maclean and Jackson, 1988).

Treatment of primary

cultures of pituitary cells with GHRH results in a rapid rise in intracellular levels of
cAMP (Bilezikjian and Vale, 1983).

Furthermore, activators of cAMP such as

forskolin stimulates not only GH release and synthesis but also growth of somatotropes
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(Billestrup, et al 1986). Calcium influx also occurs independently and may be further
enhanced by cAMP-mediated phosphorylation of calcium channels (Frohman and
Jansson, 1986). Through these and possibly other mechanisms, GHRH begins a
cascade of events that ultimately leads to phosphorylation and activation of transcription
factors responsible for increased GH gene transcription as well as events leading to
increased GH release from intrapituitary stores (Hadley, 1988). There is considerable
evidence that in the male rat, GHRH and SRIF are released in reciprocal 3 to 4 hour
cycles into the portal circulation (Plotsky and Vale, 1985) to act on the pituitary
somatotropes and generate the ultradian rhythm of GH secretion (Tannenbaum, et al
1993).
The rat GH gene is organized into 5 exons and 4 introns and spans 2 .1 kb in
length on chromosome 17 (Chien and Thompson, 1980). The mature mRNA for
growth hormone is about 1 kb in length. Within the GH promoter, two cis acting
elements, centered around -80 and -122 were found to bind a trans-acting pituitaryspecific factor termed Pit-1 (also known as GHF-1) (Nelson, et al 1988; Bodner and
Karin, 1987). As determined by RNA and immunohistochemical analysis of mouse
and rat, Pit-1 expression is pituitary-specific. Recent reports indicate, however, that a
possible exception to this rule may be hemopoetic and lymphoid tissue (Delhase, et al
1993). Pit-1 was one of the first identified members of the POU (pit-1, Qct-1,2, .unc86) homeodomain family of developmentally important transcriptional regulators which
are characterized by conservation of a 60 amino acid homeodomain and a second region
of about 75 amino acids located N terminally to the homeodomain called the POU-
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specific domain (Theill and Karin, 1993). POU domain genes constitute a subclass of
the homeobox genes, which exert critical developmental and transcriptional functions
(Finney, et al 1988).

Both the POU-specific and the homeodomain regions are

important for sequence-specific DNA binding of Pit-1 homodimers to the AT-rich Pit-1
binding sites in the GH promoter (Ingraham, et al 1988). A transactivation domain is
found near the N-terminus containing a 72 amino acid serine-threonine rich region, and
is required for high level transcriptional activity (Ingraham, et al 1990). The binding
to and transactivation of the GH promoter by Pit-1 was one of the first demonstrations
that homeodomain proteins are indeed cell type-specific transcriptional regulators
(Bodner, et al 1988). In adult rats and humans, Pit-1 expression is restricted to three
cell types within the pituitary: the GH-, prolactin (PRL)- and thyroid stimulating
hormone (TSH)-producing cells (thyrotropes). Although there has been some
controversy concerning the target genes that are activated by Pit-1, several studies have
shown that Pit-1 can transactivate both the GH and PRL genes and is also important for
regulation of the gene for the

~

subunit of TSH by TRH and cAMP (Steinfelder, et al

1991). Pit-1 also autoregulates its own expression (McCormick, et al 1990).
Studies have shown that in addition to Pit-1, other transcription factors may be
targets of the GHRH-induced intracellular signal in anterior pituitary cells, including
the proto-oncogene product C-FOS. Billestrup, et al (1987) demonstrated that GHRH
stimulation of primary somatotropes resulted in a transient increase in c-fos mRNA and
protein and that this stimulation was diminished by somatostatin. C-FOS is known to
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be important in specific differentiation events but more recent studies with growth
factors and mitogens have suggested that the expression of c-fos is a more general
response of cells to activation of protein kinase C (PKC) or increases in intracellular
levels of cAMP (Mitchell, et al 1986). The activation of c-fos in the hypothalamus and
pituitary is also associated with the stress response (Kononen, et al 1992) and has been
correlated with elevations with elevations in the stress hormone adrenocorticotropic
hormone (ACTH) (Handa, et al 1993).

It is also worth noting that experimental

evidence is accumulating for a role of c-fos expression in PRL gene regulation as well
(Davis, 1990).

D. Somatostatin (SRIF)
Somatostatin or SRIF (s.omatotropin release inhibitory factor) is a 14 amino acid
cyclic peptide isolated and sequenced by Brazeau and coworkers in 1973. Besides
inhibiting GH release, SRIF also subserves a physiologic role as a TSH-release
inhibitory factor, and also has inhibitory effects on the release of PRL from the normal
(Maclean and Jackson 1988). The discovery of somatostatin led to a new way of
thinking in the field of neuroendocrinology, for it was the first hypothalamic hormone
to be localized extensively outside that region. It has been detected in the rest of the
CNS as well as in extra-neuronal locations especially the gastrointestinal (GI) tract and
pancreas. Coincident with this widespread distribution is a diversity of functions,
besides its inhibitory effects on pituitary and GI hormones (Reichlin, 1987). SRIF
protein is first synthesized as a preprosomatostatin of 116 amino acids and is cleaved
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posttranslationally to a prosomatostatin form, which is finally processed to a 28 amino
acid form and the active 14 amino acid SRIF. In most neural tissue, SRIF-28 and and
SRIF-14 are co-secreted. The biochemical or physiologic function(s) of the pro-SRIF
fragment remain unknown (Goodman, 1983).
Somatostatinergic neurons are localized within the periventricular and anterior
zones of the hypothalamus (Maclean and Jackson, 1988). Regulation of the SRIF
release is under both neurotransmitter and hormonal control. Short and long feedback
loops have been demonstrated in response to both GH and IGF-1. Hybridization
studies to quantify steady-state SRIF mRNA levels confirm that GH exerts positive
feedback on SRIF content and synthesis (Rogers, et al 1988). Corticotropin-releasing
hormone (CRH) may stimulate SRIF release as part of its GH inhibitory effect in some
species (Rivier and Vale, 1985). Studies of the effects of neurotransmitters have
yielded conflicting results, perhaps because of diverse experimental models.
Somatostatin' s effect on target neuronal or endocrine cells is invariably
inhibitory (Maclean and Jackson, 1988). SRIF reaches the somatotropes via the
portal circulation and binds to receptors which are linked to the Gi subset of G proteins,
also known as the inhibitory G proteins. The activation of this G protein leads to an
inhibition of AC and hence a decrease in the intracellular levels of cAMP (Murray, et
al 1988). However, experiments have shown that the reduced cAMP formation cannot
entirely account for SRIF inhibition of GH release. Rather, in somatotropes as in all
other studied SRIF target tissue, binding of SRIF to its receptor inhibits stimulated
increases in intracellular calcium, which in turn prevents neurotransmitter or hormone
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release. Although SRIF leads to a decrease in secreted GH, there is no evidence that
SRIF has any affects on GH gene transcription (Maclean and Jackson, 1988). Other
hypothalamic neuropeptides, monoamines, and hormones of peripheral endocrine
organs such as thyroid hormone, adrenal glucocorticoid and gonadal steroid can be
demonstrated to exert effects on GH secretion, however, there is no convincing
evidence that they act directlyat the level of the pituitary. They may however, exert
their effects by modifying the secretion of GHRH and SRIF (Frohman, et al 1987).
To summarize, the hypothalamic regulatory peptides GHRH and SRIF up- and
down-regulate, respectively, intracellular cAMP levels and thereby affect GH
expression. This response is likely to be mediated, at least in part, via the Pit-1
binding sites, although other factors such as calcium influx and c-fos expression may
also play important roles.

E. The Prolactin (PRL) Axis
PRL is an anterior pituitary hormone which is prevalent in all vertebrates. It is
produced in and secreted from a subpopulation of pituitary cells known as
somatotropes. It is a 198 amino acid protein with an apparent molecular weight of 24
kDa (Martin, 1985). However, there is now evidence that PRL exists as a
heterogeneous molecule, having several isoforms of varying molecular weights (Clapp,

et al 1988, DeVito, 1988; Greenan, et al 1990). The function of these PRL "variants"
is the subject of much current research. Although not normally glycosylated, recent
reports indicate that PRL can undergo this type of post-translational modification
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(Bollengier, et al 1988). The biological significance of the glycosylated form of PRL
is not well understood at this time. PRL was first isolated from the pituitary, but has
subsequently been found in a variety of tissues such as the placenta (Gellerson, et al
1991), brain (Emanuele, et al 1986), prostate (Nagasawa, 1989), testes (Einson, 1978),
and lymphocyte (Clevenger, et al 1991). Like GH, PRL is involved in a wide
spectrum of functions including maintenance of lactation, reproduction,
osmoregulation, promotion of growth, and support of metabolism (Hadley, 1988).
Recently, PRL has also been implicated in regulation of the immune system (Berczi, et
al 1981; Yu-Lee, 1990), and in transcriptional activation (Clevenger, et al 1991).

Thus, unlike other pituitary hormones, PRL was not committed early in evolution to
the control of one or few related processes, but remained diversified and adaptive in
nature. In rats and humans, PRL is secreted episodically and has a half-life in the
blood of about 15 to 20 minutes (Hadley, 1988). There is a nighttime surge of PRL
secretion, which like GH, is associated with the onset of sleep. The times of onset and
duration of the PRL peak are not identical to GH, however (Neill, 1988). Pulsatile
release of PRL was thought to reflect an overlying hypothalamic control, but recent
reports indicate that such pulses originate within the pituitary gland itself (Shin and
Reifel,1981). These observations were made on hypophysectomized rats bearing renal
grafts of anterior pituitary tissue. Pulsatile PRL release was observed even when the
pituitary is physically disconnected from hypothalamic influence. Similar observations
of pulsatile PRL release from primary pituitary cells in vitro have also been reported
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(Ben-Jonathan, 1985).

F. Regulation of PRL Synthesis and Secretion
PRL gene transcription is influenced by a number of hormones including
estrogen, thyroid hormone and glucocorticoids, which act through nuclear receptors,
and dopamine (DA), thyrotropin-releasing hormone (TRH), vasoactive intestinal
peptide (VIP) and epidermal growth factor (EGF), which through membrane receptors
coupled to a variety of second messenger systems, such as the calciumcalmodulin/protein kinase C (PKC) pathway and cAMP/protein kinase A (PKA)
pathway (Davis, 1990). PRL secretion from the anterior pituitary lactotrope cells is
under tonic inhibitory control by the catecholamine dopamine (DA) which is released
by the tuberoinfundibular dopaminergic neurons of the hypothalamus (Ben-Jonathan, et

al 1989). Therefore, as opposed to GH regulation, under normal physiologic
conditions PRL synthesis is under negative rather than positive control. Although a
number of hormones, including glucocorticoids, are inhibitory, the primary negative
regulator is dopamine, acting through D2 receptors on pituitary lactotropes which are
negatively linked to AC via guanine nucleotide binding proteins (Elsholtz, et al 1991).
Thus the primary mechanism of DA action appears to be inhibition of cAMP
production. In vivo experiments have shown that transcription of the prolactin gene is
suppressed by the potent dopaminergic agonist ergocryptine (Pritchett, et al 1987),
which implies that the decrease in cAMP levels may have effects that are mediated, at
least in part at the level of transcription. Another reported prolactin inhibitory factor is
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gonadotropin-releasing-hormone associated peptide (GAP) (Nikolics, et al 1985). This
56 amino acid peptide is the carboxy-terminal portion of the peptide precursor for
gonadotropin releasing hormone (GnRH), which itself is represented by the amino
terminal 10 amino acids of the precursor. The peptide is reported to be exceedingly
potent at inhibiting prolactin secretion (Nikolics, et al 1985). However, at this point,
very little is known about GAP's mechanism of action on PRL release.
One of the best characterized positive regulators of PRL is the hypothalamic
tripeptide, thyrotropin-releasing hormone (TRH). Early studies with the GH lines of
rat pituitary cells showed that TRH is an activator of secretion of PRL and also
increases PRL mRNA levels in these cells (Tashjian, et al 1990; Dannies and Tashjian,
1976). Subsequent studies showed that the stimulation by TRH of PRL gene
expression is exerted at the level of transcription (Murdoch, et al 1983). Extensive
investigations have examined the characteristics of the TRH receptor and have
produced compelling evidence that calcium and phosphoinositides act as second
messengers in its action, and that Pit-1 is most likely the final acceptor of the signal
(Gershengorn, 1982; Martin, 1985).
The PRL gene is composed of five exons separated by four intrans. The gene
contains larger intrans than GH, spans 2.1 kb in length, and produces a mature mRNA
of approximately 900 bp (Chien and Thompson, 1980). The activity of the PRL gene
is influenced by two promoter regions: a distal enhancer region (-1713 to -1495 bp),
and the proximal promoter region containing the first approximately 200 bp of the
promoter (Lufkin and Bancroft, 1987; Day and Maurer, 1989). The distal enhancer
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region contains elements conferring responsiveness to TRH, cAMP, EGF, and contains
an estrogen response element (ERE), while the proximal promoter region shows
responsiveness to calcium, TRH, EGF, and phorbol esters (Day and Maurer, 1989;
Keech and Gutierrez-Hartmann 1989). Positive transcriptional regulation of the
prolactin gene by polypeptide hormones including TRH is conferred by short promoter
sequences that contain binding sites for the pituitary-specific transactivating factor Pit1/GHF-l (described in detail above) (Davis, 1990). Pit-1 interacts with four binding
sites within the distal enhancer and four sites within the proximal enhancer (Nelson, et
al 1986) in response to phosphorylation of the protein.

G. Similarities Between GH and PRL
GH, PRL, chorionic somatomammotropin or placental lactogen (CS), and
proliferin all belong to a family of related hormones that regulate a number of diverse
and essential physiologic processes. It is now widely accepted that these hormones
arose approximately 350 million years ago by a duplication event from a common
ancestral gene (Miller and Eberhardt, 1983).

Today, the GH and PRL genes are

located on different chromosomes (Owerbach, et al 1980) and are regulated in a cellspecific manner. GH and PRL are related by structure (Catt, et al 1967), immunologic
reactivity, and overlapping biologic activities (Niall, et al 1973). Indeed, GH has
lactogenic effects and PRL has growth-promoting effects (Murray, et al 1988). Both
are important in intermediary metabolism and both act as modulators of the immune
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system (Berczi, et al 1991). GH and PRL range in size from 190 to 199 amino acids in
different species. Each has a single tryptophan residue and each has 2 homologous
disulfide bonds. The amino acid homology between GH andPRL is 35 %. At the gene
level, the coding sequences of GH andPRL are each organized into 5 exons interrupted
by 4 introns. The genes are highly homologous in the 5' flanking regions and the
coding sequence areas and diverge in the 3' flanking regions (Theill and Karin 1993).
There is an overlap in populations of transcriptional regulators binding to the GH and
PRL gene promoters (Pit-1, for example). The splice junctions are highly conserved,
even though the introns in the PRL gene are much longer (Murray, et al 1988). It was
because of the structural and functional similarities between these two pituitary
hormones that the scope of this study was broadened to include the effects of acute
EtOH on PRL as well as GH gene expression.

H. Pharmacology of Ethanol
Ethanol (ethyl alcohol or EtOH) is rapidly absorbed from the gastrointestinal
tract or the intraperitoneal space into the bloodstream and the general circulation. It
becomes widely distributed throughout the body according to the water content of
tissue, easily penetrating the both the blood-brain and placental barriers (Leonard,
1992). The liver is the primary organ involved with the oxidation of alcohol. Alcohol
dehydrogenase (ADH) initiates the first step in the oxidation process by converting
alcohol to acetaldehyde and hydrogen ions. Acetaldehyde is then rapidly oxidized to
carbon dioxide and water by aldehyde dehydrogenase. More than 90 % of the drug is
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oxidized in the liver, while the remainder is excreted unchanged through the lungs, skin
and kidneys (Goldstein, et al 1983). Damage to tissues and organs, especially in the
liver, occurs when heavy alcohol consumption results in excess protons produced by
ADH leading to increased conversion of pyruvate to lactate, and the synthesis of
saturated fatty acids, which accumulate in the liver, impairing normal function. An
additional consequence of the excess protons is hypoglycemia, a condition which is
common amongst alcoholics (Goldstein, et al 1983).

I. Effects of Ethanol on Growth Hormone

The effects of EtOH on GH have been studied previously and the some of the
deleteriou effects alcohol exerts on this axis have been documented. Several in vivo
studies in animals (Redmond, et al 1980; Dees et al, 1988; Maureci and Conway,
1991) and humans (Valimaki, et al 1987; Valimaki et al, 1990; Aliev, 1991) have
shown that EtOH decreases serum GH after both acute and chronic administration. The
site of the acute effects of ethanol has not been precisely determined, although there is
now some evidence that suggests an alteration of hypothalamic function (Dees, et al
1988; Dees, et al 1990; Conway and Maureci, 1991). This is similar to findings in
other endocrine axes such the LHRH-LH axis (Cicero, et al 1982) and the CRH-ACTH
axis (Rivier, et al 1990) in which a hypothalamic effect of ethanol was noted. Conway
and Maureci (1991) used the adrenergic a-2 receptor agonist clonidine, which
stimulates the GH system centrally (at the level of GHRH expression), in conjunction
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with acute EtOH exposure in male rats, and showed that EtOH could block the
clonidine-induced rise in GH, leading them to conclude that this was the site of
ethanol's action. Redmond ( 1980) showed that in addition to a suppressive effect on
serum GH, acute EtOH at high doses (3 or 4 g/kg) also suppressed GH pulse
amplitude. Since GH pulse generation has both a hypothalamic and pituitary
component, this implies a dual locus of EtOH action. Additionally, it has been shown
that doses of 100-300 mg 3 EtOH added to primary pituitary cells in vitro also has the
capability of blunting GH secretion, another piece of evidence suggesting that the
pituitary is also a potential site of action (Emanuele et al 1989). Soszyinski and
Frohman (1992a) followed up the in vitro studies of Emanuele et al (1989), by
examining the effects of EtOH on signal transduction mechanisms. While differences
in results were noted, this group concluded that disruptions in cAMP-dependent
pathways were responsible for diminished GH release. Finally, there is evidence for
effects of EtOH at the liver since Sonntag and Boyd (1989) found that ethanol could
diminish levels of IGF-1 in the plasma of male rats. This result however, was only
seen after long term EtOH exposure (6 weeks). They attributed this effect, in part, to
EtOH-induced alterations in GH pulsatility, which is essential for maximal response of
IGF-1 producing liver cells to GH.

J. Effects of Ethanol on Prolactin
To date there are few studies examining the effects of prolactin in either humans
or animals. In these limited reports, however, the consensus is that EtOH results in
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significantly elevated serum PRL levels in both humans (Ylikhari, et al 1978;
Ellingboe, et al 1980; Bertello, et al 1983; Phipps, et al 1987; Soyka, et al 1991) and
rats (Chapin, et al 1980, Salonen and Huhtaniemi 1990; Seilcovich, et al 1982;
Emanuele, et al 1987; Dees, et al 1984). The exact mechanism(s) of this EtOHinduced hyperprolactinemia is unclear, but several explanations have been proposed.
At the hypothalamic level, increased hypothalamic

~-endorphin

(Schulz, et al 1980),

and reduced dopaminergic inhibition (Seilcovich, et al 1985) have been noted. Also,
substance P, which has been found to be decreased in the mediobasal hypothalamus and
increased in the pituitary with alcohol, has been postulated to account for the rise in
prolactin (Seilicovich, et al 1990). In vitro exposure of dispersed normal male rat
pituitary cells to alcohol has consistently effected a rise in prolactin secretion
(Seilicovich, et al 1984; Emanuele, et al 1987). This rise indicates that at least part of
alcohol's effects on PRL is a direct pituitary effect. Nonetheless, this does not rule out
an additional hypothalamic locus of action. Seilcovich, et al (1988) found that the
enhancement of PRL release by ethanol from the pituitary in vitro is a calcium
dependent process since omission of Ca++ from the medium results in a complete
cancellation of the ethanol effect. Finally, Sato et al (1990) proposed that the elevated
PRL may be due to ethanol-induced cell swelling, which subsequently led to a calcium
influx, a known stimulator of PRL release.
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K. Alcohol, Biological Membranes, and Second Messenger Systems
Meyer in 1901 was the first to suggest that alcohol had effects similar to general
anesthetics by dissolving into cell membranes and disrupting the lipid network that
comprises the cell wall (Hunt, 1985). It is now known that, at pharmacologically
relevant concentrations of 25-100 mM, an acute dose of EtOH increases the fluidity of
cell membranes following its acute administration, and that these changes correspond
to the sedative effects of the drug (Tabakoff, et al 1988). This suggests that EtOH
produces its effects in a relatively non-specific manner, but it is now known that
biological membranes are structurally and functionally heterogeneous and that certain
regions of the membrane are more sensitive to the disordering effects of EtOH than
others (Tabakoff, et al 1988). Thus, EtOH may affect calcium flux across a
membrane, or disrupt the intracellular phosphatidylinositol system, which in turn, may
affect the intracellular availability of calcium. This could have a serious effects on
hormone release. Thus, while it is generally believed that EtOH does not produce its
effects via a specific "alcohol receptor", some lipids do show a particular vulnerability
to the disorganizing effects of the drug (Chin and Goldstein, 1981). With regard to its
effect on hormone release, EtOH increases AC activity, and hence, cAMP
accumulation in a wide variety of cells, possibly via the membrane-bound G protein
complex (Tabakoff, et al 1988).

cAMP increases protein kinase A activity which

leads to phosphorylation of various soluble and membrane-bound proteins and results in
the physiologic effects of hormones and neurotransmitters (Alberts, 1989). The effect
of EtOH on this second messenger system appears to depend on its location. An

24
example of this is the noradrenaline-linked cyclase in the cerebral cortex of the brain.
This system seems to be directly affected by the drug, whereas the dopamine-linked
enzyme in the basal ganglia region of the brain appears to be altered by a combination
of changes in the membrane fluidity together with those in the G protein-cyclase
complex (Hunt 1985). While EtOH administration is associated with enhanced
membrane fluidity due to the disordering effects of the drug, after chronic
administration the membranes become more rigid due to an increased replacement of
the unsaturated by saturated fatty acids (Hunt, 1985).
In conclusion, GH and PRL are essential pituitary hormones with
diversephysiological roles. As such they are under highly complex regulation which
functions at numerous levels within their respective axes. Alcohol disturbs this
homeostasis, and most evidence indicates that EtOH acts in a specific, not global
fashion, and at multiple loci.

CHAPTER III
MATERIALS AND METHODS

A. Animals
All animals used in this study were adult male Sprague-Dawley rats, aged 60-90
days, obtained from Harlan Laboratories, Indianapolis, IN. Rats were received
approximately 4 days before experiments began to acclimate to surroundings so as to
minimize the effects of stress. The animals were housed in individual cages with 12
hour light: 12 hour dark regime at 22-24° C. They were given food and water ad
libitum.

B. Acute Ethanol (EtOH) Administration

Animals were treated at the same time of the day (0900) in order to minimize
the effects of ultradian rhythms in hormone levels. Animals were given a single
intraperitoneal (i.p.) injection of either sterile saline (0.9%) or EtOH (30% v/v in
sterile saline) at a dose of 1 ml per 80 g body weight (3g ethanol/kg). Control animals
were handled identically and received an injection of saline at a dose of 1 ml per 80 g
body weight. All rats were then immediately returned to their home cages in a quiet
room and given free access to food and water until time of sacrifice at 1.5, 3, 6, or 24
hours after injection. Animals involved in the repeat ethanol exposure, or "double
25
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binge" experiments were treated as above, then given a second injection of 3g/kg EtOH
or saline 24 hours after the first injection, and subsequently sacrificed at various time
points post-injection.

C. Tissue Collection
Animals were sacrificed by decapitation, calvaria removed, and the brain was
rapidly removed and dissected on ice. The hypothalamic dissection was bounded by
the optic chiasm anteriorly and the mammillary bodies posteriorly. Dissection
laterally followed the groove which separates the hypothalamus from the olfactory
tubercle rostrally, the hypothalamus from the amygdala at mid-levels, and the
hypothalamus from the optic tract caudally. Each hypothalamus was 3 mm thick,
encompassing tissue to the dorsal edge of the vertical portion of the third ventricle.
The hypothalami were placed in an autoclaved microcentrifuge tube and stored at 80°C.

Pituitary glands were carefully removed from the sella turcica and placed on a
glass plate on ice. The anterior pituitary was then gently separated from the posterior
pituitary with a blunt forceps. The posterior pitutiary was discarded. The anterior
pituitaries were immediately placed in an autoclaved microcentrifuge tube and frozen
on a dry ice/methanol bath (-800 C). The tissues were stored at -800 C until assayed.
D. Blood Ethanol Determination
At the time of sacrifice, trunk blood was collected into borosilicate glass test
tubes and kept on ice until centrifugation. Serum was obtained by centrifuging the
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trunk blood for 15 minutes at 2000 x g. Blood EtOH levels were determined using a
commercially available enzymatic kit (Sigma, St Louis, MO. cat no. 330-1). The kit is
based on the reduction of nicotinamide adenine dinucleotide (NAD) to NADH by
alcohol dehydrogenase in the presence of EtOH which results in an increase in
absorbance at 340 nm.
Three milliliters of glycine buffer (0.5 mol/L, pH 9.0) was added to each NADADH assay vial. The vial was then capped and mixed by inversion. Once the vial
reached room temperature, 10 µl of serum was added, mixed by inversion, and
incubated at room temperature for 10 minutes. The sample was transferred to a cuvette
and covered with parafilm. Absorbance was read at 340 nm on a Spectronic 21D
spectrophotometer (Milton Roy, Rochester, N. Y.). Blood ethanol concentration was
calculated from a standard curve.

E. GH Raclioimmunoassay (RIA)
The GH RIA was conducted using materials contributed by the National
Institute of Diabetes, Digestive, and Kidney disorders (NIDDK) and the National
Hormone and Pituitary Program through Dr. A. F. Parlow. Each assay tube contained
100 µl of either guinea pig anti-rabbit antibody (initial dilution 1: 10,000) or buffer
(PBS 0.01 M, 1 % BSA, 1 % normal guinea pig serum, pH 7.4) for detection of
nonspecific binding, and 100 µl of standard or unknown. GH was iodinated using the
chloramine T method. Samples were incubated at room temperature for 72 hours.
Goat anti-guinea pig second antibody, (100 µI) was then added to each tube and
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incubated for 4 hours at room temperature. Then 1 ml of normal saline (0.93) was
added to each tube, centrifuged at 2,500 rpm for 30 minutes, decanted, and the pellets
were counted on a Packard gamma counter. The intraassay coefficient was 4 3 while
the interassay coefficient was 8 3.

F. PRL Radioimmunoassay (RIA)
The PRL RIA was conducted using materials supplied by the National Hormone
and Pituitary Program and by Dr. A.F. Parlow. Each assay tube contained 100 µl of
either rabbit anti-rat antibody (initial dilution 1:2,500) or buffer (PBS 0.01 M, 1 3
BSA, 33 normal rabbit serum, pH 7.4) for detection of nonspecific binding, and 100
µl of standard (NIADDK rat prolactin RP-3) or unknown. Prolactin was iodinated
using the chloramine T method. 11 25 prolactin, (100 µI) containing approximately
10,000 cpm/tube, was added to all assay tubes and these were then incubated at room
temperature for 72 hours. Thereafter, 100 µl of goat anti-rabbit IgG, diluted 1:20 (PelFreeze Biologicals), was added and samples were incubated at room temperature for 4
hours. Then 1 ml of normal saline was added, after which the tubes were centrifuged
at 2,000 rpm at 4° C for 30 min., decanted, and pellets counted in a Packard gamma
counter. Assay sensitivity was 156 pg/ml, or 15.6 pg/ tube. The interassay coefficient
of variation was 233. The intraassay coefficient of variation was 3.83.

G. GHRH Radjojmmunoassay (RIA)
GHRH RIA was performed using an antibody donated by Dr. W.B.
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Wehrenberg (University of Wisconsin, Milwaukee). Each assay tube contained 200 µl
of either rabbit anti-rat GHRH (1:40,000 working dilution) or buffer (0.01 M PBS,
0.05 M EDTA, 1 % normal rabbit serum), 200 µl of standard (synthetic GHRH,
Sigma, St Louis, MO), or unknown, and 100 µl of 11 25 GHRH (10,000 cpm/tube). The
GHRH was iodinated by the chloramine T method. The mixture was incubated at 4°C
for 48 hours. On day three, 200 µl of goat anti-rabbit lgG (1:10 working dilution) was
added to each tube. On day 4, 300µ1of20% polyethylene glycol (PEG, M.W. 8000,
Sigma) was added to each tube, vortexed and centrifuged at 2000 x g at 4°C for 30
min. The supernatant was aspirated and the pellets counted on a Packard gamma
counter for 1 min. each. Assay sensitivity was 156 pg/ml. Interassay coefficient of
variation was 8 % and intraassay coefficient of variation was 12 %.

H. cAMP Ra<lioimmunoassay (RIA)
Intracellular pituitary cAMP levels were measured using a commercially
available RIA kit (Amersham, Arlington Heights, IL, #TRK 432), based on
competition with tritium-labelled cAMP. Individual pituitaries were homogenized in
200 µlice-cold 10 mM PBS, with 4mM EDTA added as a phosphodiesterase inhibitor.
Samples were deproteinized by boiling for 3 min. and then centrifuged at 12,000 rpm
for 10 min. The supernatant was removed to a fresh tube to be assayed.

All samples

were measured in triplicate. Radioactivity was quantified by liquid scintillation
counting, and cAMP levels were calculated from a standard curve.
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I. Tissue RNA Extraction

Total cellular RNA was isolated from pituitaries and hypothalami using a
modification of a previously published procedure (Chomczynski and Sacchi, 1987).
Tissue was collected as described above and stored at -80°C until needed. Pituitaries or
hypothalami were homogenized in 500 µl of 4 M guanidium isothiocyanate (GIT)
buffer (4M guanidine isothiocyanate, 25 mM sodium citrate, pH 7 .0, 0.5 % sarkosyl
and 0.1 M 2-mercaptoethanol). The homogenate was extracted with 50 µl 2 M sodium
acetate, pH 4.0, 500 µl phenol, and 100 µl chloroform:isoamyl alcohol 49: 1, mixed,
and incubated ice for 15 minutes. The sample was centrifuged at 10,000 x g for 15
minutes at 4°C. The aqueous phase was transferred to a new tube and the nucleic acid
precipitated by the addition of an equal volume of isopropanol and maintained on dry
ice for 30 minutes. The nucleic acid was pelleted by centrifugation at 10,000 x g for
15 minutes at 4 °C. The isopropanol was aspirated and the resulting pellet resuspended
in 100 µl of GIT. The pellet was fully dissolved by heating to 65°C with mixing.
RNA was precipitated by the addition of 0.1 volume of 3M sodium acetate pH 5.2,
and an equal volume of isopropanol, and by incubating on dry ice for 15 minutes. The
nucleic acid was pelleted. The pellet was washed with 500 µl 70% EtOH, dried at
65°C for 2 minutes, and resuspended in 200 µl of diethylpyrocarbonate (DEPC, 0.2 %)
treated water. The pellet was once more dissolved by heating to 65°C. The final RNA
sample was stored at -800C until needed. To determine the concentration of RNA in
each sample, absorbance at 260 nm was measured using 4 µl of RNA in 1 ml of
deionized, distilled water (dd H20).
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J. Northern Blot Analysis
· Total RNA (5-10 µg) was precipitated with 0.1 volume 3 M sodium acetate and
2.5 volumes of 100% EtOH on dry ice for 15 minutes. RNA was pelleted by
centrifugation at 10,000 x g at 4°C for 15 minutes, the supernatant aspirated and the
nucleic acid washed with 70% EtOH. The resulting pellet was dried at 65°C until all
residual ethanol was evaporated. The RNA was resuspended in 20 µl of RNA loading
dye (50% formamide, lX MOPS, 15% formaldehyde, 10% glycerol) and 1 µl of
ethidium bromide (lmg/ml) by heating at 65°C for 15 minutes with intermittent
mixing. After incubation at 65°C, the sample was loaded onto an agaroseformaldehyde gel and electrophoresed. Total RNA was electrophoresed through
agarose-formaldehyde gels. RNA electrophoresis was performed at 80 Vin lX MOPS
buffer. Gels were prepared with lX MOPS buffer (0.2M MOPS, pH 7.0; 50mM
sodium acetate, 10 mM EDTA), 1.1 % ultra pure agarose, and 5% formaldehyde in a
fume hood. The formaldehyde was added just prior to pouring the gel.
The gel was prepared for Northern blotting by soaking in lOX SSC at room
temperature for two 20 minute periods, with gentle shaking in order to remove
formaldehyde. During the gel washing period, a nylon reinforced nitrocellulose
membrane (Hybond M; Amersham, Arlington Hts., IL) was wetted in ddH 20 for 5
minutes, followed by a 20 minute soak in lOX SSC. The RNA was then transferred to
the membrane by capillary action for 12-16 hours. RNA was subsequently cross-linked
to the membrane using a UV crosslinker (Stratalinker, Stratagene, La Jolla CA), and
stored at -200C.
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The membranes were placed in siliconized glass hybridization tubes and prehybridized for 1-6 hours at 42°C in a rotating hybridization incubator (Robbins
Scientific, Sunnyvale, CA) The hybridization solution contained 50 3 formamide, 5X
Denhardt's solution (lX Denhardt's solution contains 0.02 3 polyvinylpyrrolidone,
0.02 3 bovine serum albumin (BSA), and 0.02 3 Ficoll 400), 0.013 sodium dodecyl
sulfate (SDS), 10 mM NaCl, 0.1 mM NaP04 (pH 6.5), 0.001 3 pyrophosphate, and
0.025 mg/ml salmon sperm DNA (heat-denatured). Labelled cDNA probes (see
below) were added to the blots with fresh hybridization solution, and allowed to
hybridize 12-16 hours at 42°C. After hybridization, the membranes were washed three
times at high stringency (0.2X SSC, 0.5 3 SDS) with rotation at 65°C, 20 minutes per
wash, in order to eliminate background signals. The membranes were then lightly
blotted on absorbent paper, wrapped in cellophane and exposed to x-ray film
(Hyperfilm M-P, Amersham) at -80°C. The autoradiographs were subsequently
developed using an x-ray film developer.
The membranes were capable of being stripped several times and reprobed with
different cDNAs without appreciable loss of RNA. This enabled multiple hormone
analyses from the same group of animals in a particular experiment. The strip solution
was prepared with 0.013 SSPE (lX SSPE contains 150 mM sodium chloride, 10 mM
sodium phosphate and lmM EDTA), and 0.253 SDS. Strip solution was heated to
boiling, poured directly onto blots, and incubated at 65°C with shaking for 20 minutes.
After three rounds of stripping, the blots were monitored with a geiger counter and
then exposed to x-ray film to verify that the radioactive probe had been removed.
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K. Labeling of cDNA Probes
Double-stranded cDNA molecules were used as hybridization probes for the
Northern blots. The probes were obtained from the following sources:
1) GH cDNA - Dr. John D. Baxter, University of California, San Francisco.
2)PRL cDNA - Dr. Richard Maurer, University of Iowa, Iowa City
3) Pit-1 cDNA - Dr. Holly A. Ingraham (Dr. Michael G. Rosenfeld's
laboratory) University of California, San Diego.
4) cjos cDNA - Dr. Tom Curran, Roche Institute of Molecular
Biology, Nutley, NJ.
5) 28s rRNA - Dr. Sullivan Reed, University of Missouri, Kansas City.

For probing Northern blots, the cDNA was labelled to high specific activity
with (alpha-32P) dCTP (New England Nuclear, Boston, MA) by the random hexamer
primer method (Feinberg and Vogelstein, 1983). Approximately 25 ng of template
cDNA was brought to a final volume of 30 µl with ddH 20 in a microcentrifuge tube
and denatured by boiling for 3 minutes, followed by quick chilling on ice for 5
minutes. The labelling reaction was prepared by adding 10 µl of 5X labelling buffer
(250 mM Tris, pH 8.0, 25 mM mgCl 2 , 10 mM DTT, 1 mM HEPES, pH 6.6, 27 A200
U/ml of hexanucleotide primer), 2 µl l.5 mM dNTPs (dATP, dGTP, dTTP, final
concentration 20 µMeach), 2 µl acetylated BSA (1 mg/ml, final concentration of 400
µgl ml), 5 µl alpha-32P dCTP (50 µCi, 3000 Ci/mmole), and 1 µI of DNA polymerase,

Kienow fragment (final concentration of 20 mM) in a final volume of 50 µl to the
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denatured template (500 ng/ml). The labelling reaction was gently mixed and
incubated at room temperature for 45 minutes. To terminate the reaction, 2 µl of 0.5
M EDTA, pH 8.0 (final concentration, 20 mM) and 48 µl of sterile water was added
to the tube and was heated to 100°C for 3 minutes, followed by a quick chill on ice for

5 minutes. Removal of unincorporated labelled dCTP was carried out by gel filtration
using Sephadex G-50 (Pharmacia, Uppsala, Sweden) spun columns. Sephadex G-50
was prepared in a 20 mM NaOH; 1 mM EDTA solution, autoclaved and stored at room
temperature. Spun columns were made from 1 cc tuberculin syringe shafts. The
Sephadex was packed by centrifugation at 1000 x g for 5 minutes. The denatured,
labelled cDNA probe was then layered on top of the column, and again spun for 5
minutes at 1000 x g. Percent radiolabelled incorporation was determined by comparing
the amount of radioactivity left in the column (unincorporated into DNA) to the
radioactivity in the column flow-through. The purified probe was then added to
hybridization tubes containing fresh hybridization solution, and the pre-hybridized
Northern blot.

Densitometric Analysis
Autoradiographs were quantitated using a scanning densitometer (Technology
Resources, Nashville TN). A two-dimensional gel analysis program was used to
quantify the area under the curve for each band scanned. The area was used for optical
density (OD) values, or arbitrary densitometer units (ADU). After analysis for
GH,PRL, and Pit-1, the membranes were reprobed with the cDNA for the 28S rRNA
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gene or the ribosomal protein gene PO to control for loading differences. Blots were
normalized using these loading controls by calculating the ratio of the ADU values for
28S for a particular sample lane to the lane with the greatest ADU for 28S. These
values were then used as correction factors by which the hormone mRNA values were
multiplied in order to account for differences due to unequal loading of the RNA gel.

M. Reverse Transcription
Three micrograms of total RNA was added to each reaction tube containing 50
mM Tris-HCL (pH 8.3), 75 mM KCL, 3 mM MgCl2 , 10 mM DTT, 2 mM of each
deoxynucleotide triphosphate (dNTP), 10 U RNasin (RNase inhibitor, Promega,
Madison, WI), 100 pmol oligo-dT primers (Bethesda Research Laboratories (BRL),
Gaithersburg, MD), and RNase-free dd H20 to a final volume of 19 µI. This mixture
was heated for 10 minutes at 65°C, then quenched on ice.

Moloney murine leukemia

virus RNase H- reverse transcriptase (200 U, Superscript, BRL) in 1 µl were added for
a total reaction volume of 20 µl and incubated at room temperature for 10 minutes and
then at 42°C for 1 hour. The reaction was terminated by heating at 95°C for 5 minutes
and quenching on ice. RNAse-H (2U) was then added to the reaction and incubated for
20 min at 37°C.
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N. .PCR Amplification
PCR Primers:
H3. 3 primers

5': 5'-GCAAGAGTGCGCCCTCTACTG-3'
3': 5'-GGCCTCACTTGCCTCCTGCAA-3'

GHRH primers

5': 5'-TGCCCCCCCTCACCTCCCTTC-3'
3': 5'-GGCGGTTGAACCTGGATCTT-3'

SRIF primers

5': 5'-GGGGATCCATGCGCCCTCGGACCCC-3'
3': 5'-GGGAATTCACAGGATGTGAATGT-3'

The oligonucleotide primers were designed to span at least one intron in order to
detect DNA contamination of RNA preparations. The locations of the primers chosen
for amplification are shown diagramatically in figure 2. The expected PCR products
using these primers were 213 bp for H3.3, 165 bp for GHRH, and 276 bp for SRIF.
Pre- and post-PCR samples were handled in different labs, using separate pipettors and
aerosol barrier tips. Five µl of reverse transcription reaction from each sample were
diluted into a final volume of 100 µl in 10 mM Tris-HCL (pH 8.3); 50 mM KCL; 1.5
mM MgC1 2 , 200 µMeach of deoxynucleotide triphosphate, 0.01 % gelatin,
0.01 %Tween-30 and 0.01 % Nonidet P-40; 2 µM of each oligonucleotide; P32-dCTP (2

µCi at 3000 Ci/mmol) and 2 U Taq polymerase (BRL). The DNA amplification was
carried out using an Eppendorf MicroCycler (Fremont, CA) programmable
heating/cooling dry block for 22 cycles of amplification. Each cycle was: 94°C for 30
sec. (template denaturation); 6QOC for 1 min. (primer annealing); 72°C for 2
min. (primer elongation).
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Figure 2. Location of oligonucleotide primers used for PCR amplification. Numbered
boxes represent exons, the lines in between the boxes represent introns. Left arrow
indicates approximate location of 5' primer, and the right arrow indicates approximate
location of the 3' primer.
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This was followed by one extended elongation step of 10 min. at 72°C. These
conditions were established using control DNA substrates. A reaction was performed
as described above, but without the addition of reverse transcriptase as a test for the
presence of contaminatinng genomic DNA in the RNA from the tissues. As a further
control, oligonucleotide primers alone without any RNA were used. Ten µl of the
sample was electrophoresed on a 1.5 % agarose gel, transferred to a Nytran membrane
(Schleicher and Schuell, Keene, NH) and exposed to autoradiographic film and
analyzed using a scanning densitometer. The GHRH and SRIF signals were
normalized to H3.3 to control for sample to sample variation.

N. Nuclear Run-On Transcription Assay
The following nuclear run-on procedure was modified for this study from two
previously published methodologies (Kafatos, et al 1979; Danerji, et al 1984). Binding
of plasmids to nitrocellulose was performed as follows: Plasmids containing the target
and control cDNAs were linearized by digestion with a restriction enzyme which cuts
the plasmid once and outside of the inserted cDNA. The linearized DNA was then
denatured in ice cold 10 N NaOH for 30 min. An excess of each plasmid cDNA (20
µg in 500 µl) was spotted onto a nitrocellulose filter using a slot blot apparatus

(Minifold II, Schleicher and Schuell, Keene, NH). The slots were rinsed with 500 µl
6X SSC. 'Dte filters were baked for 1 hour at 80°C under vacuum, then stored
dessicated at -200C until needed. The run-on labelling of nascent RNAs was carried
out as follows (all procedures were carried out on ice unless otherwise indicated):
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Three pituitaries from each experimental group were pooled and homogenized using a
dounce homogenizer in cell lysis buffer (0.25 M sucrose, 55 mM HEPES pH 7.4, 5
mM MgCl2 and 0.1 % Triton X-100. The nuclei were isolated by layering the
homogenate over a 0.5 M sucrose cushion and centrifuging at 6,000 rpm for 10
minutes. The pelleted nuclei were resuspended in a synthesis buffer containing 200
µCi
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P-UTP (Amersham, Arlington Heights, IL), 0.5 mM each rGTP, rATP, rCTP,

17% glycerol, 60 mM HEPES pH 7.0, 2 mM DTT, 25 mM ammonium sulfate, 3mM
magnesium acetate, 3 mM MnC12 , and 5 mM sodium fluoride. After incubation at 37°
C for 30 minutes, the reaction was stopped by adding 600 µl of stop buffer (2 % SDS, 7
M urea, 350 mM LiCl, 1 mM EDTA, 10 mM Tris, pH 8.0), 80 µl of 10 mg/ml
proteinase K, and 10 µl of 10 mg/ml tRNA and incubating at 42° C for 1 hour. The
newly synthesized, labeled RNA was precipitated by addition of 100% TCA, chilling
on ice for 20 mins., and centrifuging at 12,000 rpm for 15 minutes. The labeled RNA
pellet was then carefully resuspended in 100 µl TE with 0.5 % SDS using a pipettor
fitted with a wide bore tip. 1 ml of prehybridization solution (50% formamide, 6X
SSC, lOX Denhardt's solution, 0.2 % SDS) was added to the pellet suspension, gently
mixed, and added to a tube containing a nitrocellulose blot of cDNA plasmids which
was pre-hybridized for 3 hours at 42°C.

Blots were hybridized for 72 hours in sealed

tubes at 42°C. After hybridization, the filters were washed with progressively
increasing stringency (6X SSC, 0.2 % SDS for 20 minutes; 2X SSC, 0.2 % SDS for 20
minutes; 0.2 % SSC, 0.2 % SDS for 20 minutes) all at 65°C. The filters were dried
briefly, wrapped in cellophane and exposed to X-ray film (Hyperfilm M-P, Amersham,
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Arlington Hts., IL).
To confirm that an equal number of nuclei were collected from saline-injected
control and EtOH-treated pituitaries, a 10 µl aliquot of the nuclei suspension was
removed and counted manually in quadruplicate using a standard hemocytometer
(Hausser Scientific, USA), on a light microscope (Nikon Model TMS-F, Japan). As
an additional control, a second aliquot was taken from the labeled nuclei, placed in a
scintillation vial containing 5 mls of scintillation cocktail, and counted on a beta
counter (Beckman LS 7500). No significant differences between control and EtOH
nuclei preparations were found using these procedures.

0. Statistics
Data was calculated as mean

± standard error of the mean.

One-way analysis

of variance (ANOV A) with a Bonferroni t-test follow-up was performed as a statistical
test for differences between control and ethanol-treated animals on the RIA data and
mRNA and semi-quantitative PCR data. When data was expressed as percent of
control, statistical analysis was performed on the raw data, which was then converted to
percent of control values. Significant differences were reported for p < 0.05.

CHAPTER IV
RESULTS

A. "Binge" Ethanol Animal Model
Adult male Sprague Dawley rats were used for these studies. EtOH was
administered via a single intraperitoneal injection for the single binge experiments, or
two injections, on consecutive days for the double binge experiments as described in
the materials and methods chapter. This model allowed each animal to represent an n
of 1, since it was possible to measure serum levels of GH andPRL, pituitary GH
andPRL content, cAMP content, as well as perform the various molecular analyses
from individual animals. The exception to this was the nuclear run-on assays which,
due to assay sensitivity, required pooling three pituitaries together for an n of 1. In the
earlier single binge experiments, the time points used were 0.5, 1.5, 3.0, and 24 hours.
When experiments were expanded to the double binge model, a 6 hour time point was
added to better follow trends in the time course during the span between 3 and 24
hours. The time points of 1.5, 3.0, and 24 hours remained constant throughout.

B.

Blood Ethanol Concentrations for Single and Double Binge Models

Blood ethanol (EtOH) concentrations were measured on trunk blood collected at
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time of sacrifice, using a commercial enzymatic assay kit (see materials and methods
for details). Typical blood EtOH concentrations at selected time points after a single
i.p. injection of EtOH (3g/kg), (single binge) are shown in Figure 3. Each value
represents the mean

± standard error of the mean (SEM) of 5-6 animals.

Blood EtOH

levels averaged 88 mM 30 minutes after administration, 62 mM at 90 minutes, 56 mM
at 180 minutes, 43 mM at 6 hours and undetectable ( < 1 mM) at 24 hours. Figure 4
shows blood EtOH concentrations after repeated (double binge) EtOH exposure, the
levels at 30 minutes averaged 91 mM, 68 mM at 90 minutes, 62 mM at 180 min, and
50 mM at 6 hours. Again, at 24 hours there was no detectable EtOH present, nor was
there any EtOH noted in the saline treated animals at any time point (data not shown).

C. Effects of Single Binge EtOH on GH Protein and mRNA levels
Serum GH levels as measured by radioimmunoassay (RIA) are shown in Figure
5. Large variations in serum GH levels were measured in the control, saline-injected
animals and this probably reflects the normal pulsatility in GH secretion noted by
others (Tannenbaum et al 1979; Jansson, et al 1985; Bercu et al 1991). Because of this
high degree of variability, and for the purpose of clarity, the results in this and other
figures in this thesis were expressed as percent of control. Values were calculated as
means

± SEM,

then converted to percent of control and statistical analyses were then

peformed. Despite this highly variable baseline, serum GH levels were significantly
depressed at 0.5, 1.5 and 3 hrs. in the single binge EtOH-treated animals compared to
values in saline-injected controls. At 0.5 hr. after injection, the levels of serum EtOH
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Figure 3. Blood ethanol concentrations after single binge treatment. Serum ethanol
concentrations were determined from trunk blood at time of sacrifice using a
commercial kit (see Materials and Methods). Animals were treated with a single
intraperitoneal (i.p.) injection of 3g/kg EtOH Each value represents mean ethanol
concentration

+ SEM of 6-12 animals at each time point.
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Figure 4. Blood ethanol concentrations after double binge treatment. Serum ethanol
concentrations were determined on trunk blood at time of sacrifice using a commercial
kit. Blood was taken from animals given two i.p. injections of 3g/kg EtOH on
consecutive days. Each value represents mean ethanol concentration ± SEM of 6-12
animals at each time point.
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Figure 5. Serum GH levels after single binge EtOH treatment. Trunk blood was
obtained at 0.5, 1.5, 3 and 24 hrs after an i.p. injection of EtOH or saline. Serum GH
was measured by RIA. GH levels were significantly depressed at the 0.5, 1.5 and 3
hr. time points when compared to saline-injected controls; while the trend downward
was still present at 24 hrs., this was not significant. N =5-6/group. (Data is expressed
as percent of control (100%). *p

< .05; ** p < .01)
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group had fallen to values that were 18 3 of control animals (p < 0.05). At 1.5 hr. the
levels in the EtOH group were 25 3 of control values (p < 0.05), and at 3 hrs. the
EtOH group had serum GH levels that were 263 of control (p<0.01). Serum GH
remained suppressed 24 hrs. after injection in the EtOH group at 43 3 of controls, but
this difference did not achieve statistical significance.
Pituitary GH content was unchanged between the two groups after single binge
EtOH treatment at any time point examined. Again, because of the high degree of
variability between animals in the control groups, values are expressed as percent of
control (Fig. 6). The pituitary GH content of the EtOH treated animals were 72 3 of
control at 0.5 hr.; 803 of control at 1.5 hr after injection; elevated to 2063 of control
at 3 hrs and 204 3 of control 24 hrs after injection. While a trend toward increased
pituitary GH content was noted at 3 hrs. (30,900
63,800

+ 20,500 ng/ml

+ 7200 ng/ml

in the control group vs

in the EtOH group), this did not achieve statistical

significance. At 24 hrs. there was also a tendency for the GH content to be higher in
the EtOH group (29, 100 + 16,900) compared to the EtOH exposed animals (59,400 +
29,400 ng/ml) but this was not significant.
The steady-state pituitary GH mRNA levels were measured by Northern blot
analysis, and the results are shown graphically in Figure 7. GH mRNA levels were
modestly, but significantly decreased by single binge EtOH, as compared to salineinjected controls, at 0.5 and 1.5 hours, time points associated with the fall in serum GH
(Fig 5). At 0.5 hours GH mRNA levels were 71 3 of control, (p < 0.05); at 1.5
hours, GH mRNA levels were 67 3 of control, (p < 0.05). By 3 hours post-injection,
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Figure 6. Pituitary GH content after single binge EtOH treatment. Pituitary GH was
measured by RIA in animals given a single i.p. injection of EtOH and sacrificed at time
points indicated. No significant difference was found at any time point, although there
was a trend for EtOH animals to have higher GH content at 3 and 24 hrs. N =56/group. (Data is expressed as percent of control.)
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Figure 7. Pituitary GH steady-state mRNA levels after single binge EtOH treatment.
GH mRNA levels were assessed by Northern blot analysis on rats given a single i.p.
injection of saline of EtOH, and sacrificed at time points indicated. The mRNA for
GH was significantly depressed at 0.5 and 1.5 hrs. N =5-6/group. Values were
obtained by densitometric scanning of autoradiograms from Northern blot analysis and
expressed in arbitrary densitometer units (ADU). The data was corrected for loading
as explained in the Materials and Methods section. (Data is expressed as percent of
control. * p < .05)
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the GH mRNA levels in the EtOH group were not significantly different from controls,
(83%) as were the animals at 24 hours (116%).

D. Effects of Single Binge EtOH on PRL Protein and mRNA Levels
In contrast to the results for serum GH, serum PRL values were significantly
higher in the EtOH animals at 1.5 (11
EtOH group) and 3 hours (8

+ 2 in the control group vs 23 + 5 ng/ml

+ 2 vs 22 + 3 ng/ml control vs EtOH)

in the

(Fig. 8). At the

earliest time point, 0.5 hours, serum PRL was virtually identical in both groups, (11.5

± 3.5 vs 12 ± 2.7 ng/ml) By 24 hrs., there was no change between the two groups in
serum prolactin levels (10

+

1 ng/ml control; 7

+

1.5 ng/ml EtOH). Also in contrast

to serum GH, there was much less variation among the control groups, as evidenced by
the smaller SEMs, even though PRL is also released in a pulsatile fashion (Hadley,
1988).
Pituitary PRL content was not different between control and EtOH groups at
any time point (Fig. 9). Although there was an upward trend at 1.5 hrs in the EtOH
exposed animals (210% of control level) this was not statistically significant, most
likely due to high degree of variability in PRL content between animals. At 3 hrs the
values were nearly identical in the two groups, EtOH treated animals were 96% of
control nor was there a difference at 24 hours, EtOH treated animals were at 93 % of
control averages.
PRL mRNA levels were significantly decreased at 1.5 and 3.0 hrs in EtOH
treated animals (Fig. 10). Interestingly, these are the time points associated with
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Figure 8. Serum PRL levels after single binge EtOH treatment. Time course effect of
a single i.p. injection of saline or EtOH on serum PRL levels 0.5, 1.5, 3 and 24 hrs
after injection, as measured by RIA. Prolactin was significantly elevated after EtOH at
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+ SEM of 5-6 animals
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Figure 9. Pituitary PRL content after single binge EtOH treatment. PRL content was
measured by RIA at various time points after single binge EtOH or saline. There were
no statistical differences between the 2 groups at any time point studied. Data
represent mean PRL content± SEM. n=5-6 per group.
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Figure 10. Pituitary PRL steady-state mRNA levels after single binge EtOH treatment.
The mRNA levels, as measured by Northern blot analysis, were significantly decreased
at 1.5 and 3 hrs. in the EtOH-treated animals, with a return to to control levels by 24
hrs. Data was corrected for loading as explained in the Material and Methods section
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clevated serum PRL levels (Fig. 8). At the 1.5 hour time point, PRL mRNA levels are
59% of control (p<0.05), and at 3 hours post-injection PRL mRNA levels are 65% of
control (p < 0.05). The effect is gone by 24 hours, with an insignificant amount of
suppression that is 78 % of control levels.
The steady-state mRNA levels for Pit-1, the transcription factor responsible for
high level expression of GH and PRL, were also measured by Northern blot to
determine if the EtOH-induced effects on GH and PRL mRNA were indirectly related
to decreased synthesis of Pit-1. However, there was no difference between the 2
groups at any time point studied (Fig. 11). At 1.5 hours, the values were .27
control vs .3

± .01 EtOH,

ADU; at 3 hours, .24

± .02 vs

.25

± .1

± .03; and at 6 hours,

.42 ± .06 vs .47 ± .11.

E. Effects of Double Binge EtOH on GH protein and mRNA
To determine if the the GH axis responds in a similar fashion to a repeated
challenge with ethanol, a repeat exposure or "double binge" experiment was conducted.
Serum GH levels fell dramatically 1.5 and 3 hours after the second EtOH injection
compared to levels in saline injected animals (Fig. 12). A similar effect was observed
after a single EtOH injection (Fig. 5). At 1.5 hours after injection, serum GH fell to
6% of control value and at 3 hours, 12 % of control. The effect dissipated, however, at
6 hours when EtOH treated animals had 85 % of control levels of serum GH, and at 24
hours where there was in fact, an insignificant elevation in GH values in the EtOH
group to 143 % of control levels after the second EtOH injection (Fig. 12). Data are
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Figure 11. Pit-1 (GHF-1) steady-state mRNA levels after single binge EtOH
treatment. The mRNA levels of Pit-1, as measured by Northern blot were found to be
unaltered by EtOH exposure at any time point studied. (Data is expressed as percent of
control). Values represent mean ADU

± SEMand were corrected for loading as

described in the Materials and Methods section. n=5-8 per group.
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Figure 12. Serum GH levels as measured by RIA obtained from animals exposed to
two IP injections of EtOH or saline given 24 hours apart and sacrificed 1.5, 3, 6, and
24 hours after the second injection. GH levels were significantly lower in the EtOH
animals at 1.5 and 3 hours after treatment. n = 9 animals per group at each time
point. * = p < .05.
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presented as percent of control due to the high degree of variability of GH values in
saline injected animals. Such variability was not, however, seen in the EtOH-injected
rats. For example, at 1.5 hours after saline treatment, serum GH values ranged from
13 ng/ml to 537 ng/ml and at 3 hours from 5 ng/ml to 394 ng/ml. However, serum
GH levels in EtOH exposed animals were all between 3 and 41 ng/ml.
In contrast to the results of single binge experiments (Fig. 7), steady state levels
of GH mRNA, as measured by Northern blot were unchanged by double binge EtOH
exposure at any of the measured time points (Fig. 13). At 1.5 hours post-injection,
GH mRNA was 1203 of control in the EtOH treated animals, at 3 hours, GH mRNA
was 101 3 of control, at 6 hours, GH mRNA was 873 of control and at 24 hours it
was 90 3 of control.

F. Effects of Single and Double Binge EtOH on Hypothalamic Hormones
To determine if acute EtOH exposure has an influence on the release of GHRH
from the hypothalamus, and hence, lead to a decrease in steady-state GH mRNA and
GH secreted from the pituitary, hypothalamic GHRH content was measured by RIA
after single binge EtOH exposure (Fig. 14). The levels of hypothalamic GHRH
content were not altered by EtOH at any time points examined, indicating that secretory
defects in GHRH neurosecretory cells are most likely not involved in the decreases in
serum GH and GH mRNA after single binge EtOH.
Hypothalamic growth hormone-releasing hormone (GHRH) and somatostain
(SRIF) mRNA are expressed at low levels in the rat and were beyond the lower limits
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Figure 13. Pituitary GH mRNA levels after double binge EtOH treatment as measured
by Northern blot analysis. Data represent mean

± SEM ADU, corrected for loading

and converted to percent of control. There were no significant differences noted at any
time point studied. n = 5 animals per group at each time point.

58

c::J CONTROL
I
0:::
I
C>

1250

~EtOH

1000

1.5

Figure 14.

3.0
6.0
TIME (hours)

24
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expressed as pg/ml and corrected for mg protein. There were no significant differences
noted at any time point studied. n= 6 animals per group.
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of sensitivity of Northern blots performed in our laboratory (data not shown).
Therefore, a semi-quantitative reverse transcription-polymerase chain reaction (RTPCR) technique was developed, utilizing histone 3.3 (H3.3) as an internal control.
H3.3 was chose as an internal control because it is expressed in a constitutive and cell
cycle-independent manner in all cells (Wells, et al 1987), and in experiments
performed in our laboratory, appears to be unaffected by EtOH exposure (Kelley et al,
1993)(data not shown). Furthermore, unlike most members of the histone multigene
family, its mRNA product is polyadenylated, allowing oligo dT-primed reverse
transcription (Wells, et al 1987). As demonstrated previously, and as shown in Figure
15, the amount of PCR product for both GHRH and H3.3 increased in a linear fashion
to a plateau with increasing number of PCR cycles (Kelley et al, 1993). Aliquots of a
standard PCR reaction containing hypothalamic cDNA, GHRH and H3.3
oligonucleotide primers were removed after 20, 25, 30, 35, and 40 cycles. The
products were run on an agarose gel, blotted, and the signals scanned densitometrically
and plotted as relative amount vs number of PCR cycles as shown in Figure 15. Based
on the results of these experiments, the range of linearity was determined to be between
20 and 25 cycles, which was on the ascending portion of the curve. Subsequently, 22
cycles was utilized for these studies (Fig. 15). A linear relationship between the
amount of starting RNA and the amount of PCR product was also demonstrated,
establishing this as a relatively quantitative tool in our laboratory (Fig 16), (Kelley, et

al 1993). Subsequent experiments utilized 3 µg of total RNA as starting material.
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Panel A shows the resulting DNA blot. Panel B is a graphic representation of the gel
shown in Panel A. Relative amount refers to arbitrary densitometer units
experiment was performed three times with similar results.
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Relative amounts of GHRH mRNA were quantified from individual hypothalami,
obtained from rats exposed to single and double binge experiments. In the single binge
experiment, EtOH induced a significant rise in GHRH mRNA levels at 3 and 6 hours
after injection when compared to control animals (at 3 hours EtOH values were 379%
of control, p < 0.05; at 6 hours EtOH values were 232 % of control, p < 0.05) (Figs. 17
and 18). In the double binge experiments, only at the 3 hour time point was the EtOH
group significantly elevated when compared to controls (229% of control, p < 0.05)
(Figs 17 and 18). Ninety minutes after EtOH treatment, a time when serum GH was
markedly decreased, GHRH mRNA was unchanged (Figure 18). However at 3 hours,
with serum GH still dramatically reduced, GRF mRNA rose sharply. By 24 hours after
either single or double injections of EtOH, GHRH mRNA returned toward control
levels.

Representative blots of the PCR products at the 3 and 6 hour time points are

shown in Figure 17.
Similar RT-PCR reactions were peformed on the same RNA samples as above
for quantitation of the hormone responsible for inhibiting GH release, somatostatin
(SRIF). Again, H3.3 was used as an internal control for reverse transcription and PCR
amplification. Conditions for running the SRIF RT-PCR reactions were determined by
performing experiments similar to those described above, using varying amounts of
starting RNA and running the reactions for 20, 25, 30, 35 and 40 cycles to find the
linear portion of the amplification curve. The results were similar to those for GHRH,
that is, 22 cycles of PCR with 3 µg of starting RNA were found to be the optimal
conditions (data not shown).

Unlike GHRH, however EtOH did not affect SRIF
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Figure 18. Densitometric analysis of hypothalamic GHRH (GRF) mRNA, as
determined by semi-quantitative RT-PCR, in animals treated with a single (Panel A) or
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steady-state mRNA levels, as measured by semi-quantitative PCR, in either single
binge or double binge models at any time points measured (Figs. 19 and 20).

G. Effects of Acute EtOH on Hormone Transcription Rates
Nuclear run-on transcription assays were performed to determine if a decrease
in the rate of transcription of the GH and PRL genes could account, in part, for the
decrease in the steady-state levels of these hormones at various time points after single
binge EtOH exposure. The results indicate that EtOH can, in a time-dependent
manner, decrease the rate of transcription of the GH, PRL and Pit-1 genes. The most
striking decrement was observed at 3 hours post EtOH injection, and a representative
autoradiograph and corresponding densitometric plot of this time point is shown in
Figure 21. Actin, used as a positive loading control was unchanged by EtOH treatment
at this or any other time point studied. PBR 322 is empty bacterial plasmid DNA ,
used as a negative control for non-specific binding; there is negligible binding of
labeled RNAs to PBR 322 in all the blots. Densitometric readings are represented
graphically for the time points studied in Figures 22 and 23. Each value represents the
mean ± SEM for the ADU. For each time point, n=2-3, with an n of 1 representing
3 pooled pituitaries. At 1.5 hours, GH, PRL and Pit-1 had reduced transcription
rates. GH levels were 1490

± 351 control vs

1007

± 26 EtOH,

ADU;PRL was 522

± 62 vs 312 ± 89; Pit-1 was 344 ± 24 vs 219 ± 22 (Fig. 22). At 3 hours, the
decrement was greater for all three genes, GH levels were 845 ± 41 control vs 298 ±
13 EtOH, ADU; PRL was 195 ± 13 vs 108 ± 14; Pit-1was110 ± 16 vs 45 ± 17.

66

_J

0
0:::

c:=i CONTROL

z

~EtOH

f--

0

u

150

LL

0
1-

z,....,

w::::>

uo

0::: <(

w....._.,
(L

<(

z

0:::

E
LL

0:::
(/")

1.5

3.0
6.0
TIME (hours)

24

Figure 19. Hypothalamic SRIF levels after single binge EtOH as determined by semiquantitative RT-PCR. Relative amounts of SRIF mRNA were determined after a single
i.p. injection of saline or 3g/kg EtOH, as described in the Materials and Methods
section. There were no significant differences between control and EtOH-injected
animals at any time point studied. Results are expressed in ADU and were converted
to percent of control.
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measured by the nuclear run-on transcription assay . See Materials and Methods for
details. Panel A depicts typical blot of run-on at 3 hour time point. The blot was
scanned and the results are depicted graphically in Panel B. Values are expressed in
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Figure 22. Graphic representation of the effects of EtOH on hormone transcription
rates at 1.5 and 3 hours after treatment, as measured by the nuclear run-on transcription
assay. Animals were treated with a single injection. Panel A depicts the results after
1.5 hours. GH,PRL and Pit-1 transcription rates are suppressed by EtOH to varying
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the largest EtOH-induced fall in GH transcription rates. PRL and Pit-1 transcription
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significantly suppressed at 3 hours (p<0.05). Values are expressed as mean ADU &
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At 6 hours, GH transcription rate was slightly increased by EtOH, 482

± 146 control

vs 535 ± 199 EtOH, ADU; PRL was 134 ± 48 vs 90 ± 4; and Pit-1 was still
decreased almost 50-fold at 112 ± 35 vs 67 ± 10 (Fig. 23). 24 hours after treatment,
GH transcription rate was still moderately, but not statistically elevated, 457
control vs 567

± 243 EtOH;

PRL rates were virtually unchanged 185

±

± 112

143 vs. 210

± 41; and Pit-1 was still mildly suppressed, 106 ± 9 vs 76 ± 30 (Fig 23).

H. Effects of Acute EtOH on lntrapituitary cAMP Levels
Since cAMP is an important second messenger molecule involved in both GH
andPRL synthesis and secretion (Hadley, 1988; Neill, 1988), and cAMP has been
shown to be altered by acute EtOH treatment (Tabakoff et al 1988), a short time course
experiment measuring intra-pituitary cAMP after single binge EtOH treatment was
performed. Intracellular cAMP was measured by RIA and the results, reported as
pmol/pituitary are shown in Figure 24. The intrapituitary cAMP levels were elevated
significantly at 0.25 hours after single binge treatment in the EtOH animals (9

± .65

control vs 29.3 ± 3.4 EtOH pmol/pit., p < .05), at 0.5 hours, there was a significant
ten-fold rise in cAMP in EtOH animals (6.0

+ .78 vs 58.5 + 7.5 pmol/pit., p<0.01)

with a rapid return to control values by 1.5 (18
hrs. (12.6

+

.6 vs 17.4

+ 2.3) (Fig.

24).

+

.54 control vs 21

+

.9 EtOH) and 3
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Figure 24. The effects of EtOH on intrapituitary cAMP levels at various time points
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I. Effects of Acute EtOH on c-jos Expression

A short time course experiment was performed to measure the response of the
c-fos gene to acute EtOH exposure. c-fos is stress responsive (Kononen et al, 1992)
and has been correlated with GH and PRL gene expression (Billestrup et al, 1987;
Davis, 1990). c-fos expression was measured in pituitaries by Northern blot analysis at
15 min., 30 min., 1 hour, 2 hours and 3 hours after a single injection of EtOH (3g/kg)
or saline. A representative autoradiograph of a Northern blot is shown in Figure 25.
c-fos mRNA is rapidly induced 15 minutes after EtOH exposure to levels that are
nearly 50-fold greater than control (1.68

± 0.92 control vs 24.39 ± 2. 7 EtOH,

p < 0.05). This effect persists to a lesser degree after 30 minutes, when EtOH treated
animals had an almost 10-fold increase in induction of c-fos than controls ( 2. 95
control vs 20.99

±

± . 13

10.6 EtOH). The induction quickly abated, which is typical of

auto-regulated genes such as c-fos, and from 1 hour to 3 hours there were
unmeasurable levels of c-fos mRNA in either control or EtOH treated pituitaries by
Northern blot analysis (Fig. 25).
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Figure 25. Time course effects of single binge EtOH treatment on pituitary c-fos
mRNA levels. Steady-state mRNA levels of cfos were measured by Northern blot
analysis. A representative autoradiograph is depicted. At each time point, there were
2 control samples and 2 EtOH samples. The blot was simultaneously probed with the
cDNA for 28s rRNA to control for loading differences. cfos mRNA is rapidly
induced (50-fold) 15 min after EtOH treatment when compared to saline-injected
controls. At 30 min after EtOH treatment, cfos mRNA levels were still elevated over
control, but to a lesser degree (10-fold). This effect quickly dissipated, and there is no
difference between EtOH and control groups at any remaining time points examined.
This experiment was performed three times with similar results .

SUMMARY OF RESULTS
Table I. Pituitary
"SINGLE BINGE"
Pituitary
Content

Serum

mRNA

GH

a,b,c

NC

a,b

Prl

b,c

NC

b,c

"DOUBLE BINGE"
Serum
GH

Pituitary
Content

mRNA

--

NC

b,c

Table II. Hypothalamus
"SINGLE BINGE"
HT Content
GHRH

NC

SRIF

--

mRNA
c,d
NC

"DOUBLE BINGE"
HT Content
GHRH

--

SRIF

--

mRNA
c
NC

a) 0.5 hours after ethanol
b) 1.5 hours after ethanol
c) 3.0 hours after ethanol
d) 6.0 hours after ethanol
NC: no change
--: not measured

injection
injection
injection
injection
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CHAPTER V
DISCUSSION

The endocrine system, like the central nervous system, is adversely affected by
alcohol abuse. The pituitary hormones in particular seem vulnerable to EtOH's effects,
potentially leading to a wide range of endocrine dysfunctions, since anterior pituitary
hormones are responsible for a variety of physiologic and biochemical functions
including growth, reproduction, immune regulation, stress response and carbohydrate
and protein metabolism (Hadley, 1988). The overall goal of the present study was to
further characterize the adverse effects of acute EtOH exposure on the GH and PRL
gene expression, pituitary hormones of vital importance, in the male rat. In addition,
efforts were made to elucidate some of the possible mechanisms underlying the EtOHinduced disruption of normal GH and PRL regulation. This included measurements of
gene expression in response to acute EtOH exposure and alterations in regulatory
hypothalamic releasing and inhibiting hormones as well as effects on second messenger
systems. As has been observed in other hormone systems, results of the present study
indicate that EtOH acts at multiple levels within the GH and PRL axes and that no
single site of action is solely responsible for the overall effects of the drug.
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A. The Effects of Ethanol on Growth Hormone
Many studies have demonstrated that alcohol exerts a negative effect on the GH
axis in male rats (Redmond 1980; Mannisto, et al 1987; Dees, et al 1988; Emanuele,
et al 1992; Sontag and Boyd 1989). In the present acute study, this observation was

confirmed. A single dose of EtOH at 3g/kg ("single binge" model) was sufficient to
cause a rapid and profound decrease in serum levels of GH. As early as 30 minutes
after ethanol administration, serum GH levels fell significantly, and remained
suppressed through the 3 hour time point. After repeated alcohol exposure, as shown
in "double binge" experiments described here, the pattern is essentially the same, with
significant suppression at 1.5 and 3 hours post EtOH. Since pituitary GH content
remained statistically unchanged after EtOH treatment, there is no direct evidence that
a defect in secretion is the cause of this suppression. It may be, however that secretion
is affected to some degree, but this is not appreciable due to the vast store of GH
present in the pituitary. GH content did increase in this study, at 3 and 24 hours after
EtOH treatment, but the effect did not reach statistical significance, most likely due to
a high degree of variability between animals. Bercu et al (1991) observed that sex
differences in GH secretory patterns of rats was due to differential responsiveness to
growth hormone-releasing hormone (GHRH). EtOH could lead to intracellular
perturbations that cause diminished response to GHRH and produce a lowered GH
secretory pattern. Interestingly, there was a very large range in measured
immunoreactive serum GH in control, saline injected rats, which was not seen in the

78
EtOH treated animals. This large variation was anticipated in light of the long
recognized episodic nature of GH secretion and similar observations by others of wide
swings in GH levels when individual animals were sampled only once, as in the present
study (Emanuele, 1992; Zeitler, 1991; Frohman, 1986; Tannenbaum, 1991). In the
EtOH animals there was no such variation suggesting that the normal surges of GH
secretion were abolished by EtOH. In studies of animals sampled repeatedly, EtOH
has, in fact, been shown to do this (Redmond, 1980).
An alternative explanation for the decrease in serum GH is that EtOH somehow
leads to increased metabolic clearance of the hormone from the bloodstream. In this
model, alcohol could induce liver enzymes that would speed up GH protein turnover.
However this might also be expected to result in increased clearance of PRL as well,
and in light of increased serum PRL, this does not seem to be the case.
Finally, the possibility exists that the decrement in serum GH is due to a stress
effect of handling and injections or of ethanol itself, since GH secretion is suppressed
in rats by stress (Bercu, et al 1991). However, control animals are handled in an
identical manner as EtOH animals and given an injection of an equal volume of saline,
without showing diminished GH levels. The "stress of intoxication" in these alcohol
naive rats may play a role in the GH suppression, but the fact that EtOH can suppress
GH secretion from pituitaries in vitro argues against this (Emanuele, et al 1989).
The EtOH-induced suppression of GH mRNA suggests that EtOH may have an
impact not only on GH secretion but on GH synthesis as well. The results described
here have also shown a decrease in steady-state levels ofPRL mRNA but not in the
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levels of the transcription factor Pit-1 (GHF-1). Pit-1 is a POU/homeodomain
transcription factor shown to be important in regulation of both GH and PRL (as well
as thyrotropin) transcription (Mangalam, et al 1989). The observation of no change in
Pit-1 mRNA levels does not rule out the possibility that other alterations in this protein
may have taken place as a result of EtOH exposure. For example, changes in the
phosphorylation state of Pit-1 can affect the DNA binding capabilities and
transactivation potential of this factor (Mangalam, et al 1989). Further studies are
required to determine if this is the case. The results observed in this study of
decrements in GH and PRL mRNA, but not Pit-1 message indicate that the effects of
EtOH on pituitary hormone mRNAs are not global. This is in agreement with recent
reports that intraperitoneal EtOH administered to castrated male rats resulted in a
dramatic 803 reduction in LHp mRNA, but no change in FSHp mRNA or the mRNA
for the common a-subunit for these hormones (Emanuele, et al 1991). This change
was coupled with significant falls in serum levels of both LH and FSH. The biological
significance of the modest 30 % decrease in GH and PRL mRNA is difficult to
determine. However, any disruption in gene expression has the potential for farreaching effects given the importance of these hormones. The findings of no change in
pituitary GH mRNA in the double binge model reported here is at variance with the
single binge data, showing a modest but statistically significant fall in GH mRNA after
a single binge. The reasons for this discrepancy are unclear, but in a recent study
examining GH mRNA levels in animals exposed to EtOH for 6 days a similar lack of
change was noted (Soszynski, 1992b), indicating that repeated or long-term exposure
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may lead to compensatory mechanisms being activated.
Since steady-state mRNA levels in a cell represent a balance between the
intracellular processes of synthesis (transcription) and degradation (targeted nuclease
digestion) (Peltz, et al 1991), attempts were made to discern whether the changes
observed were due to alterations in the balance of these processes. Nuclear run-on
transcription assays were performed to determine if acute EtOH had the ability to alter
the rate of transcription of the GH and PRL gene, leading to a decrease in the steadystate mRNA levels. The results of these experiments indicate that alcohol can influence
the rate of transcription of GH and other genes in a time-dependent fashion. At 3
hours after injection, the time point associated with the largest fall in serum GH and
steady-state GH mRNA levels, the amount of nascent GH mRNA was approximately
(30) % of control levels. Transcription rates were also repressed for the PRL and for
the Pit-1 gene (50% of control levels), indicating that the effects of EtOH are
pervasive, and that hormone gene expression in the pituitary is affected at multiple
levels.
However, it should be noted that the decrease in the transcription rate of the GH
gene in response to EtOH cannot fully explain the decreases in serum GH and steadystate GH mRNA levels since the published half-life of GH mRNA is in the range of 1224 hours (Gertz, et al 1987; Yaffee and Samuels 1984). Also, no change in Pit-1
steady-state mRNA levels was observed at times when Pit-1 transcription rates were
diminished. An alternative possibility or contributing factor is an EtOH-induced
decrease in the stability of the GH mRNA molecules leading to an increase in the

81
turnover rate of this message and hence, less mRNA translated into protein. GH
mRNA half-life can be dramatically lengthened or shortened through changes in
stability by various agents including other hormones (Carter et al 1993). Diamond and
Goodman (1985) reported that in the absence of thyroid hormone, the GH mRNA halflife in culture was reduced from 20 hours to 2 hours.
It is also possible that EtOH is affecting some other hormone such as thyroid

hormone, and indirectly destabilizing the GH message. While this is an attractive
possibility, the current techniques to measure half-lives are not feasible in an in vivo
system. The application of transcriptional inhibitors such as actinomycin D or thiolutin
to cells in culture is a well-accepted method for measuring rates of mRNA turnover in
response to various agents (Parker et al 1991). While this type of measurement in
pituitary cells cultured in the presence or absence of EtOH could yield valuable data on
alcohol's effects on pituitary hormone half-lives, the results may not be relevant to the
present study due to differences inherent in in vitro versus in vivo systems (physical
separation from hypothalamic influences in vitro, for example). Additionally,
transcriptional inhibitors administered to animals would effectively halt all
transcription, including genes which may affect GH regulation in other ways, masking
or confusing the effects of the alcohol alone.
Another factor which has been suggested to be associated with changes in
mRNA stability is poly-A tail length (Peltz, et al 1991). Hormones, growth factors
and pharmacologic agents are known to affect poly-A tail length of a number of
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mRNAs including those of GH and PRL (Murphy et al, 1992; Carter et al, 1993).
Attempts were made to determine if acute EtOH exposure in this study led to changes
in GH or PRL transcript size. The results showed a slight, but most likely
insignificant, decrease in GH transcript size in EtOH-treated animals when run on high
percentage agarose gels (data not shown). More sensitive techniques are required to
determine if this effect is real or artifactual.

B. The Effects of Ethanol on Prolactin
As has been previously described by several laboratories (Chapin, et al 1980;
Bertello, et al 1983; Salonen and Huhtaniemi, 1990), acute EtOH treatment in this
study led to a significant increase in the levels of serum PRL in male rats. This effect
is rapid, with PRL levels raised significantly over controls at 1.5 and 3 hours after
single binge EtOH treatment. The action of ethanol on serum PRL levels could result
from a stimulatory effect on the secretion of a residual PRL reserve in the pituitary or
be secondary to a direct effect on DA levels in the hypothalamus. Though there was a
higher average PRL content in pituitaries of alcohol-treated rat 1.5 hours after
injection, this was not significantly different from controls, nor were there any
significant differences in PRL content between alcohol and control groups at any time
point examined. Other investigators have found pituitary prolactin content decreased
after chronic alcohol exposure (Salonen and Huhtaniemi, 1990). This finding argues in
favor of increased secretion of PRL in response to alcohol and neatly explains the
raised serum PRL levels, but this result could not be duplicated in the present, acute
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exposure study. This may be due to one of several situations. First, it may well be that
the actual amount of extra secreted PRL is small compared to the total pituitary PRL
pool and thus any pituitary differences might be so low as not to be easily detected.
Indeed, the average rise in serum PRL between EtOH and control groups of 12-14
ng/ml, reflects an increased total secretion of only 120-140 ng, assuming distribution
through a 10 ml volume of rat blood. Such an amount would be small when compared
to the approximately 25,000 ng total content of pituitary PRL seen in these studies.
The rise in serum PRL after acute EtOH exposure reported here has also been
demonstrated in in vitro studies of male rat pituitary cells (Emanuele, et al 1987) and
by others in male rat (Seilicovich, et al 1982) and has been attributed to the "stress"
effect of drinking on this stress-responsive hormone. Similarily, the ability of ethanol
to increase the activity of the hypothalamic-pituitary-adrenal axis, another stressresponsive hormonal system, has been documented in both acute and chronic studies
(Rivier, et al 1984). An EtOH induced increased rate of CRF biosynthesis was noted
(Rivier, et al 1990) in addition to an altered ability of CRF or stress to stimulate ACTH
secretion. The mechanisms through which these stress changes take place, however
remains speculative. Numerous changes in the brain levels and/or rate of turnover of
neurotransmitters such as dopamine, acetylcholine and norepinephrine have been
reported after EtOH exposure (Hunt, et al 1979), in addition to effects on thyrotropin
releasing hormone (Rudeen and Zoeller 1991) which is known to regulate PRL release.
The fact that ethanol alters the secretion of a brain neurotransmitter, however, only
suggests a potential role for this mediator in EtOH-induced hormone changes, without
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explaining the mechanisms involved in this change.
As previously mentioned, PRL mRNA was significantly supressed at 1.5 and 3
hours after acute EtOH administration. It is difficult to reconcile this observation with
the significantly increased levels of PRL protein in the serum at these same time points.
However, this result serves to demonstrate that the processes of gene regulation and
hormone secretion are not inextricably linked. It also demonstrates once again that the
effects of acute EtOH on endocrine cells is selective and not global, as some systems
within the same cell are increased, while other are decreased.

C. The Effects of EtOH on Hypothalamic Regulatory Hormones
Another goal of the studies reported here was to determine the impact of EtOH
in this single and double binge model on the synthesis of GHRH, and somatostatin
(SRIF) the two major hypothalamic hormones controlling pituitary GH (Frohman,
1986; Tannenbaum, 1991). As previously discussed, serum GH is suppressed after
both single and double binge alcohol exposure, at 1.5 and 3 hours after treatment.
While hypothalamic GHRH content was unchanged, single binge alcohol significantly
increased the steady-state mRNA for this hormone, at 3 and 6 hours post treatment.
The increase in GHRH mRNA also occurred at the 3 hour time point in the double
binge experiment, a time when serum GH levels were still markedly depressed. Since
GH itself has been shown to have a negative feedback effect on GHRH mRNA (Zeitler,
1991; Frohman, 1986; Tannenbaum, 1991), this rise in GHRH mRNA, at a time when
GH was sharply reduced, becomes all the more significant. GHRH mRNA levels then
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gradually returned to control levels by 24 hours.
Taken together, these data suggest an interesting model. The drop in serum GH
and the subsequent rise in GHRH mRNA represents the hypothalamus reacting to the
continued fall in serum GH. At later time points, as EtOH metabolites are cleared and
GH mRNA levels and serum GH normalize (in response to elevated GHRH), GHRH
itself falls toward control levels. After prior exposure to alcohol, the response may be
more rapid, with no alterations in GH mRNA levels. It thus appears that the
hypothalamic-arcuate nucleus neuronal system is rapidly responsive to perturbations in
ambient levels of GH. Since somatostatin mRNA levels are unaffected by EtOH, it
appears that the control point is at the level of GHRH.

D. Effects of Acute EtOH on Second Messenger Systems in the Pituitary
The sharp ten-fold rise in pituitary cAMP levels after acute EtOH treatment is
intriguing. The data presented here reflects total pituitary cAMP and, thus, it cannot
be determined whether EtOH's effect is seen in all the different cell populations of
pituitary (e.g. lactotropes, somatotropes, gonadotropes, etc.) or is restricted to a few.
The former possibility is more likely the case since data from several other laboratories
have consistently demonstrated that EtOH acutely causes enhanced cAMP accumulation
in a diverse variety of cells including hepatocytes, (Hoek, et al 1981), NIE-115
neuroblastoma cells (Gayer and Gordon), PC12 cells (Rabe and Weight, 1988) and
platelets (Gordon, et al 1986). Thus, it seems reasonable to suppose that the cAMP
response to EtOH in pituitary cells is a generalized cellular phenomenon, and our
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findings of increased total pituitary cAMP reflect rises in each of the cellular subtypes.
It is relevant that cAMP has been shown to stimulate transcription and steady-state

levels of the, GH and PRL genes as well as secretion of both of these hormones. The
elevated cAMP levels seen in our EtOH treated rats compared to control rats might
then be expected to result in substantial increases in steady-state levels of GH and PRL
mRNA's. Thus, the 303 decrement in GH andPRL messages in EtOH treated rats and
the lack of apparent change in Pit-1 message might be inappropriate in light of the
sharp cAMP rise. There are several potential explanations for this. It may be that
EtOH did not raise cAMP levels in somatotrope or lactotrope populations in the
pituitary, leaving the possibility open for decreased GH and PRL gene transcription,
and/or diminished stability of these messages. This seems unlikely in light of evidence
that EtOH enhances intracellular cAMP accumulation in response to GRH, indicating
that somatotropes may be targeted by EtOH (Soszynski and Frohman 1992a).
Alternatively, EtOH could be inducing GRF and TRH receptor down regulation via
cAMP elevation. In other cell systems, cAMP is known to mediate receptor downregulation via phosphorylation after cAMP and protein kinase A have been activated
(Collins, et al 1991). Also, the discrepancies may be explained by desensitization of
cAMP-dependent pathways of intracellular signalling by high cAMP levels (Hausdorff,

et al 1990). Therefore, in the system described here, the decrease in GH and PRL
mRNA levels might be attributed to diminished GRF and/or TRH receptor number on
pituitary cells secondary to EtOH-induced cAMP elevation. A final potential
explanation for the elevated cAMP levels could be the known increase in membrane
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fluidity that occurs in response to EtOH exposure (Hoek, et al 1988). Most
investigators, however, agree that bulk membrane lipid pertubations do not totally
account for the deleterious actions of EtOH, and there is unanimity of opinion that
specific targets within the cell membrane exist for EtOH (Tabakoff, et al 1988).
Further studies involving membrane fluidity measurements in pituitary cells exposed to
EtOH are required to determine the degree of this potential influence. Although the
cAMP response to EtOH is short-lived, it should be noted that a short-term activation
of signal transduction systems may result in the phosphorylation of a wide range of
intracellular target proteins, effects that may persist for a considerable period of time
after the actual exposure to ethanol has subsided.
The results showing a rapid induction of the c-fos gene with acute EtOH
treatment raises some interesting possibilities. The induction may be part of a stress
response to alcohol, but not handling or injection stress since control animals were not
induced to the same level (fig 25). Alternatively, it represent a non-specific
perturbation of the pituitary membrane and a subsequent activation of protein kinase
pathways. Studies have shown that cAMP is a positive regulator of cjos mRNA levels
in BALB/c 3T3 fibroblasts, provided the cells recieve a simultaneous signal, probably
calcium influx (Ran, et al 1986). Therefore, a third possibility is the c-fos induction
seen in the present study may be a secondary response to cAMP elevation, since both
events occur very rapidly after exposure to EtOH and in the same general time frame
(compare figs. 24 and 25) and, EtOH added to pituitary cells in culture has been shown
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to result in a calcium influx into these cells (Sato, et al 1990). Correlations have been
made between c-fos induction and GH and PRL gene expression (Billestrup, et al 1987;
Davis, 1990). However, as is the case for the increase in cAMP, it is difficult to
ascertain which systems may be affected by the transient increase in c-fos, since
measurements were made in whole pituitaries, which are composed of many cell types.
There may be at least a functional relationship between the PRL gene and that of c-fos.
Although c-fos has a very general role in cell function, it shares marked calcium
dependence with the PRL gene (Bandyopadhyay and Bancroft, 1989), and c-fos mRNA
levels are regulated similarly to prolactin secretion (Gourdji, et al 1989). Moreover,
one report suggests that the c-fos gene was amplified in cells from a human prolactinsecreting tumor (U, et al 1988). In this study elevated serum PRL is seen 1.5 hours
after EtOH exposure fitting into a time frame which may account for c-fos stimulation.
This fails to explain however the fall in serum GH at the same time point. A functional
link between c-fos and the GH and PRL genes remains speculative, but it may be of
interest in that even transient elevations of this transcriptional activator could have
long-lasting effects on cell function.
In summary, the studies reported here provide further insight into the molecular
and physiological mechanisms by which EtOH disrupts pituitary GH and PRL
secretion. These and other studies suggest that EtOH acts both at the brain and anterior
pituitary levels. Further, this study indicates that within these loci, EtOH has multiple
effects including alterations in steady-state mRNA levels, gene transcription rates,
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secondary messenger systems and hormone secretory dynamics. The effects of EtOH
are selective, and not global in nature. Some hormone systems are affected at many
levels, while others remain unchanged by the drug. Additionally, these studies indicate
that the GHRH-GH system, though initially affected by EtOH, is able to compensate
for these disturbances and operates rapidly to restore GH homeostasis, especially when
subjected to repeated ethanol exposure.
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